Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data for the novel, potential ...

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ ... updated ivonescimab data in advanced triple-negative breast cancer (TNBC), recurrent / metastatic head and neck squamous cell carcinoma ...

The presentation was entitled, The safety and efficacy of ivonescimab in combination with chemotherapy as first-line (1L) treatment for triple-negative breast cancer (TNBC), presenting the current ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ ... a phase 2 study that enrolled 43 patients with stage I-III triple-negative breast cancer (TNBC). Patients in the study underwent short-term ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data ...

Two Oral Presentations Featured Updated Ivonescimab Data from Phase II Studies in CRC and TNBC in Addition to Poster Presentation on HNSCC Encouraging Phase II Data Supports the Continuing Expansion ...

A team of researchers at NYU Abu Dhabi (NYUAD), led by Program Head of Chemistry Ali Trabolsi, have developed nanoscale ...

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative ...

Researchers have discovered new insights into tumor-induced B cell changes in blood and bone marrow of triple negative breast cancer patients. The findings show two distinct patterns of B cell ...

Triple-negative breast cancer is and remains a more aggressive subtype of breast cancer, and there has always been an urgent need to find more effective therapies. Prior to KEYNOTE-522 becoming the ...

In KEYNOTE-522, treatment with neoadjuvant pembrolizumab and chemotherapy, followed by adjuvant pembrolizumab, led to ...